Latest Articles
- ArticleAcute effects of alemtuzumab infusion in patients with active relapsing-remitting MSKatja Thomas, Judith Eisele, Francisco Alejandro Rodriguez-Leal, et al.April 29, 2016
- ArticleEvidence of a pathogenic role for CD8+ T cells in anti-GABAB receptor limbic encephalitisKristin S. Golombeck, Kathrin Bönte, Constanze Mönig, et al.April 29, 2016
- EditorialA link between long-term natalizumab dosing in MS and PMLPutting the puzzle togetherEugene O. Major, Avindra NathApril 29, 2016
- ArticleClinical utility of testing AQP4-IgG in CSFGuidance for physiciansMasoud Majed, James P. Fryer, Andrew McKeon, et al.April 20, 2016
- ArticleWidespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRIMorten Blaabjerg, Klemens Ruprecht, Tim Sinnecker, et al.April 20, 2016
- ArticleCirculating miR-150 in CSF is a novel candidate biomarker for multiple sclerosisPetra Bergman, Eliane Piket, Mohsen Khademi, et al.April 20, 2016
- ArticleNormal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSDCarsten Finke, Josephine Heine, Florence Pache, et al.April 20, 2016
- Clinical/Scientific NotesTumefactive brain lesion with rapid cavity formation associated with anti-aquaporin-4 antibodyTakuya Uehara, Goichi Beck, Kousuke Baba, et al.April 14, 2016
- Clinical/Scientific NotesCervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesionsRachel E. Ventura, Ilya Kister, Sohae Chung, et al.April 14, 2016
- ArticleMultiple sclerosis and risk of young-adult-onset Hodgkin lymphomaScott Montgomery, Mohammadhossein Hajiebrahimi, Sarah Burkill, et al.April 14, 2016
Pages
Advertisement
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker